{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:36:31Z","timestamp":1794544591308,"version":"4.9.1"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"10","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>The current state of research on the anti\u2011SARS\u2011CoV\u20112 potential of artemisinin\u2011related compounds has identified arteannuin B as a potent inhibitor of the nCoV\u20112019BetaCov\/Wuhan\/WiV04\/2019 and BetaCov\/Italy\/CDG1\/2020 strains of the virus. The aim of this work was to fractionate the targeted sesquiterpenoid compounds, arteannuin B and artemisinin, from the complex matrix of the crude ethanolic leaf extract of Artemisia annua L. using high\u2011speed countercurrent chromatography (HSCCC) and to test the simplified or purified fractions against the genomically characterized Alpha SARS\u2011CoV\u20112 variant in vitro. This is the first detailed in vitro anti\u2011SARS\u2011CoV\u20112 study using an analytically characterized supercritical fluid extract of A. annua L. The preparative HSCCC method enabled the isolation of purified arteannuin B in a single chromatographic step, which was confirmed by LC\u2011ESI\u2011QTOF\u2011MS\/MS. The MS data confirmed the selectivity of the HSCCC method for the targeted fractionation of artemisinin from the complex matrix, as it was successfully separated from the EtOH crude extract without co\u2011elution with arteannuin B. Antiviral activity determined by quantitative real\u2011time PCR (qRT\u2011PCR) yielded half\u2011maximal effective concentrations (EC\u2085\u2080) of 93.7 \u00b5g\/mL (SC\u2011CO\u2082 extract), 173.5 \u00b5g\/mL (EtOH extract), 187.3 \u00b5g\/mL (artemisinin knockout fraction), 38.1 \u00b5g\/mL (arteannuin B fraction), and &gt;100 \u00b5g\/mL (artemisinin). The arteannuin B fraction was highly active at 50 \u00b5g\/mL (p &lt; 0.0001) and 100 \u00b5g\/mL (p &lt; 0.0001), and inhibited the amplification of the SARS\u2011CoV\u20112 N and RdRp genes by 84% and 100%, respectively. An important contribution of this study is the demonstration of the antiviral activity of arteannuin B against the Alpha variant of SARS\u2011CoV\u20112, which is known to have increased infectivity and transmissibility.<\/jats:p>","DOI":"10.17305\/bb.2025.12052","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T22:51:13Z","timestamp":1745535073000},"page":"2345-2363","source":"Crossref","is-referenced-by-count":3,"title":["Profiling of sesquiterpenoid fractions from &lt;i&gt;Artemisia annua&lt;\/i&gt; L. and testing their &lt;i&gt;in vitro&lt;\/i&gt; anti-SARS-CoV-2 activity"],"prefix":"10.17305","volume":"25","author":[{"given":"Irma","family":"Gu\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilma","family":"Terzi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Eterovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adis","family":"Softi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160ejla","family":"Goleti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teufik","family":"Goleti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Nikoli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Kori\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Bijeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Nik\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senka","family":"Vidovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Duri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2025,4,25]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/12052\/3912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/12052\/3912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:03:08Z","timestamp":1761084188000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/12052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":0,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.17305\/bb.2025.12052","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}